Topical Insulin for Glaucoma and Optic Neuropathies
Stanford University
Summary
The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Capable to provide informed consent * Diagnosis of optic neuropathy either glaucoma or NAION or optic disc drusen. * Only one eye per patient will be selected as the study eye - if both eyes meet the inclusion criteria, the eye with the worse acuity and /or visual field will be selected. The contralateral eye will be left untouched. Exclusion Criteria: * Pregnant or breastfeeding woman * Presence of any ocular pathologies other than glaucoma that contributes to the severe vision loss (retinopathy / maculopathy, severe uveitis, keratopathy, etc.) * Diagnosis of glucose…
Interventions
- DrugInsulin, 4 units
Topical insulin 100 U/ml, 1 drop per day
- DrugInsulin, 20 units
Topical insulin 500 U/ml, 1 drop per day
- Druginsulin, 4 units twice daily
1 drop of low dose insulin twice daily.
- Druginsulin, 20 units twice daily
1 drop of high dose insulin twice daily
- Druginsulin, 4 units three times daily
1 drop of low dose insulin three times daily.
- Druginsulin, 20 units three times daily
1 drop of high dose insulin three times daily.
Location
- Byers Eye Institute at Stanford UniversityPalo Alto, California